Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of Cancer"
DOI: 10.7150/jca.72066
Abstract: Purposes: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used for patients with gefitinib (first-generation EGFR-TKI) resistance, but osimertinib resistance inevitably occurs. Therefore, it is necessary to explore the mechanisms of osimertinib…
read more here.
Keywords:
764 mapk1;
circ7312;
osimertinib resistance;
resistance ... See more keywords